4%-Yielding Gilead Sciences' Potential Path To A $100 Stock Price
Gilead Sciences has a robust pipeline in oncology and HIV, indicating sustained growth potential. The company offers dividends, buybacks, and an attractive valuation, making it an appealing investm...
WHO's new COVID guidelines see fewer patients requiring hospitalization
Most patients are unlikely to develop severe disease or die if they get the current variants of COVID-19 as immunity levels have climbed given higher levels of vaccination.
Buying the dip in high-yield Gilead Sciences
Gilead Sciences NASDAQ: GILD share price tanked following the Q3 release on what was otherwise a good report. The company is gaining traction in key markets, sustaining its core business, and offse...
Gilead Sciences, Inc. (GILD) Q3 2023 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and ...
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street es...
Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $1.90 per share a year ago.
Gilead Sciences 3Q results top estimates on cancer and HIV drug sales
Gilead Sciences Inc after Tuesday's close announced third quarter 2023 adjusted earnings per share (EPS) of $2.29, surpassing the analyst consensus forecast of $1.91, according to Zacks Equity Rese...
Gilead stock rises on top-, bottom-line beats
Gilead Sciences Inc.'s GILD, -0.65% stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped analyst revenue and earnings estimates. Gile...
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (...
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.
7 Healthcare Stocks to invest in for a Healthy Future
One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best opti...
Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs
Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with an initial focus in hepatitis B virus and hepat...
Related Companies